Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press45610.36691/RJA456ArticlesСтатьиResearch ArticleNew opportunities for treatment of severe bronchial asthma: from clinical studies to portraits of patientsНовые возможности лечения тяжелой бронхиальной астмы: от клинических исследований к портретам больныхNenashevaN MНенашеваН М1444031@gmail.comRussian Medical Academy for Postgraduate EducationГБОУ ДПО Российская медицинская академия последипломного образования15062015123NO3 (2015)№3 (2015)516110032020Copyright ©; 2015, Pharmarus Print MediaCopyright ©; 2015, Фармарус Принт Медиа2015Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/456

The proportion of patients with controlled asthma has increased over the last 15 years, however, still there is a significant proportion of patients who do not achieve control of the disease, and therefore have a high risk of exacerbations, hospitalizations, and poor quality of life. Patients with severe asthma, for which there were limited additional pharmacotherapy are the major problem. For the first time in recent years in the treatment of asthma a new class of drugs appeared: longacting anticholinergics - tiotropium which had been entered in stepwise therapy of asthma by GINA 2015. The definition of severe asthma, the role of the cholinergic nervous system in bronchial asthma, mechanism of action and clinical efficacy of tiotropium in severe bronchial asthma adults are described in the article.

За последние 15 лет увеличилось число пациентов с контролируемым течением бронхиальной астмы, однако по-прежнему существенна пропорция больных, которые не достигают контроля заболевания, а стало быть, имеют высокий риск развития обострений, госпитализаций и низкое качество жизни. особую проблему составляют пациенты с тяжелой астмой, для которых существовали ограниченные возможности дополнительной фармакотерапии. Впервые за последние годы в лечении астмы появился препарат нового класса: длительно действующий антихолинергик - тиотропий, внесенный в ступенчатую терапию астмы по GINA 2015. В статье обсуждаются вопросы определения тяжелой астмы, роль холинергической нервной системы при бронхиальной астме, механизм действия и клиническая эффективность тиотропия при тяжелой бронхиальной астме у взрослых.

bronchial asthmaasthma controlsevere asthmatiotropiumбронхиальная астмаконтроль астмытяжелая астматиотропийGINA 2014, 2015 www.ginasthma.org.Chuchalin A.G., Khaltaev N., Santonov N. Chronic respiratory diseases and risk factors in 12 regions of the Russian. Federation International Journal of COPD. 2014, v. 9, р. 963-974.Rabe K.F., Vermeire P.A., Soriano J.B., Maier W.C. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur. Respir. J. 2000, v. 16, р. 802-807.Price D., Fletcher M., Thys van der Molen. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim. Care Respir. Med. 2014, v. 12, Article number: 14009; doi: 10.1038/npjpcrm.2014.9; published online 12 June 2014.Архипов В.В., Григорьева Е.В., Гавришина Е.В. Контроль над бронхиальной астмой в России: результаты многоцентрового наблюдательного исследования НИКА. Пульмонология. 2011, № 6, с. 87-93.Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am. J. Respir. Crit. Care Med. 2004, v. 170, р. 836-844.Chung K.F., Wenzel S., Brozek J. et al. International ERS/ ATS guidelines on definition, evaluation and treatment of severe asthma. Eur. Respir. J. 2014, v. 43, р. 343-373.Berry М., Morgan A., Shaw D. et al. Pathological Features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax. 2007, v. 62, р. 1043-1049.Haldar P., Pavord I.D., Shaw D.E. et al. Cluster analysis and clinical asthma phenotypes. Am. J. Respir. Crit. Care Med. 2008, v. 178, р. 218-224.Gillisen A. Patient’s adherence in asthma. J. Physiol. Pharmacol. 2007, v. 58, р. 205-222.Paganin F., Seneterre E., Chanez P. et al. Computed tomography of the lung in asthma: influence of disease severity and etiology. AJRCCM. 1996, v. 153, р. 110-114.Sorkness R.L., Bleecker E.R., Busse W.W et al. Lung function in adults with stable but severe asthma: Air trapping and incomplete reversal of obstruction with bronchodilation. J. Appl. Physiol. 2008, v. 104, р. 394-403.Hardin М., Silverman E., Barr G. et al. The clinical features of the overlap between COPD and asthma. Respir. Res. 2011, v. 12, р. 127.Rootmensen G.N., van Keimpema A.R., Jansen H.M. et al. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J. Aerosol. Med. Pulm. Drug. Deliv. 2010, v. 23, р. 323-328.Yohannes A.M., Connolly M.J., Hanania N.A. Ten years of tiotropium: clinical impact and patient perspectives. Int. J. COPD. 2013, v. 8, р. 117-125.Adams K.S., Lowe D.K. Tiotropium for adults with inadequately controlled persistent asthma. Ann. Pharmacother. 2013, v. 47, р. 117-123.Nadel J.A., Barnes P.J. Autonomic regulation of the airways. Ann. Rev. Med. 1984, v. 35, р. 451-467.Disse B., Reichl R., Speck G. et al. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci. 1993, v. 52, р. 537-544.Joos G.F. Potential usefulness of inhibiting neural mechanisms in asthma. Monaldi Arch. Chest. Dis. 2000, v. 55, р. 411-414.Haddad el-B., Rousell J. Regulation of the expression and function of the M2 muscarinic receptor. Trends Pharmacol. Sci. 1998, v. 19, р. 322-327.Ayala L.E., Ahmed T. Is there loss of protective muscarinic receptor mechanism in asthma? Chest. 1989, v. 96, р. 1285-1291.Coulson F.R., Fryer A.D. Muscarinic acetylcholine receptors and airway diseases. Pharmacol. Ther. 2003, v. 98, р. 59-69.Gosens R., Zaagsma J., Meurs H., Halayko A.J. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir. Res. 2006, v. 7, р. 73.Ishihara H., Shimura S., Satoh M. et al. Muscarinic receptor subtypes in feline tracheal submucosal gland secretion. Am. J. Physiol. 1992, v. 262, р. 223-228.Amishima M., Munakata M., Nasuhara Y. et al. Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway. Am. J. Respir. Crit. Care Med. 1998, v. 157, р. 1907-1912.Wessler I.K., Kirkpatrick C.J. The non-neuronal cholinergic system: an emerging drug target in the airways. Pulm. Pharmacol. Ther. 2001, v. 14, р. 423-434.Fujii T., Kawashima K. An independent non-neuronal cholinergic system in lymphocytes. Jpn J. Pharmacol. 2001, v. 85, р. 11-15.Reinheimer T., Baumgärtner D., Höhle K.D. et al. Acetylcholine via muscarinic receptors inhibits histamine release from human isolated bronchi. Am. J. Respir. Crit. Care Med. 1997, v. 156, р. 389-395.Profita M., Giorgi R.D., Sala A. et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy. 2005, v. 60, р. 1361-1369.Hagforsen E., Einarsson A., Aronsson F. et al. The distribution of choline acetyltransferase- and acetylcholinesterase-like immunoreactivity in the palmar skin of patients with palmo-plantar pustulosis. Br. J. Dermatol. 2000, v. 142, р. 234-242.Wessler I., Kilbinger H., Bittinger F. et al. The non-neuronal cholinergic system in humans: expression, function and pathophysiology. Life Sci. 2003, v. 72, р. 2055-2061.Gosens R., Zaagsma J., Grootte Bromhaar M. et al. Acetylcholine: a novel regulator of airway smooth muscle remodelling? Eur. J. Pharmacol. 2004, v. 500, р. 193-201.Haddad E.B., Mak J.C., Barnes P.J. Characterization of [3H] Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol. Pharmacol. 1994, v. 45, р. 899-907.Barnes P.J. Tiotropium bromide. Expert Opin. Investig. Drugs. 2001, v. 10, р. 733-740.Heung-Woo Park. The role of tiotropium in the management of asthma. Asia Pac. Allergy. 2012, v. 2, р. 109-114.Pitcairn G., Reader S., Pavia D., Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J. Aerosol Med. 2005, v. 18 (3), p. 264-272.Disse B., Speck G.A., Rominger K.L. et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999, v. 64, р. 457-464.Gross N.J. Tiotropiumbromide. Chest. 2004, v. 126, р. 1946-1953.Ohta S., Oda N., Yokoe T. et al. Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clin. Exp. Allergy. 2010, v. 40, р. 1266-1275.Buels K.S., Jacoby D.B., Fryer A.D. Non-bronchodilating mechanisms of tiotropium prevent airway hyperreactivity in a guinea-pig model of allergic asthma. Br. J. Pharmacol. 2012, v. 165, р. 1501-1514.Wollin L., Pieper M.P. Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD. Pulm. Pharmacol. Ther. 2010, v. 23, р. 345-354.Bos I., Gosens R., Zuidhof A. et al. Inhibition of allergen-induced airway remodeling by tiotropium and budesonide: a comparison. Eur. Respir. J. 2007, v. 30, р. 653-661.Park H.W., Yang M.S., Park C.S. et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy. 2009, v. 64, р. 778-783.Peters S.P., Kunselman S.J., Icitovic N. et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N. Engl. J. Med. 2010, v. 363, р. 1715-1726.Kerstjens H.A., Disse B., Schröder-Babo W. et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial. J. Allergy Clin. Immunol. 2011, v. 128, р. 308-314.Bateman E.D., Kommann O., Schmidt P. et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J. Allergy Clin. Immunol. 2011, v. 128, р. 315-322.Kerstjens H.A., Engel M., Dahl R. et al. Tiotropium in asthma poorly controlled with standard combination therapy. N. Engl. J. Med. 2012, v 367, р. 1198-1207.O’Connor B.J., Towse L.J., Barnes P.J. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am. J. Respir. Crit. Care Med. 1996, v. 154, р. 876-880.Terzano C., Petroianni A., Ricci A. et al. Early protective effects of tiotropium bromide in patients with airways hyper responsiveness. Eur. Rev Med. Pharmacol. Sci. 2004, v. 8, р. 259-264.FitzGerald M., Moroni-Zentgraf P., Engel M. et al. Once-daily tiotropium Respimat® add-on therapy improves symptom control across severtiies of symptomatic asthma, independent of allergic status. Poster 64426 presented at the ATS Conference. Denver, USA, 2015.Magnussen H., Bugnas B., J. van Noord et al. Improvements with tiotropium in COPD patients with concomitant asthma. Respiratory Medicine. 2008, v 102, р. 50-56.